Photo from wikipedia
Trials in cardiogenic shock are difficult to perform because of challenges in recruitment: logistics play a role (time-dependent disease) but informed consent is the most complex step; slowness of enrolment… Click to show full abstract
Trials in cardiogenic shock are difficult to perform because of challenges in recruitment: logistics play a role (time-dependent disease) but informed consent is the most complex step; slowness of enrolment calls for multicentre international consortia to optimize their flow. Yet, the average duration of cardiogenic shock trials is extremely long: DanGer Shock (NCT0 1 633502) started in 20 1 2 and subsequently included centres from Ger-many to fasten enrolment which is now (after 1 0years) almost to be achieved. 1 This phenomenon is not marginal as such a long period might encompass major changes in milestones of therapy around the primary intervention which might significantly impact the clinical practice and the expected results: this would eventually produce an impact on study size and inconclusive findings. in cardiogenic to or show consent
Journal Title: European Journal of Heart Failure
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!